43 Stock Overview
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
electroCore, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.45 |
| 52 Week High | US$6.95 |
| 52 Week Low | US$3.66 |
| Beta | 0.93 |
| 1 Month Change | -2.68% |
| 3 Month Change | -21.01% |
| 1 Year Change | -6.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 49.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| 43 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0.9% | 2.6% | 1.2% |
| 1Y | -6.0% | -8.3% | 2.0% |
Return vs Industry: 43E0 exceeded the German Medical Equipment industry which returned -8.3% over the past year.
Return vs Market: 43E0 underperformed the German Market which returned 2% over the past year.
Price Volatility
| 43 volatility | |
|---|---|
| 43 Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 4.7% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 43E0's share price has been volatile over the past 3 months.
Volatility Over Time: 43E0's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 68 | Dan Goldberger | www.electrocore.com |
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance.
electroCore, Inc. Fundamentals Summary
| 43 fundamental statistics | |
|---|---|
| Market cap | €32.25m |
| Earnings (TTM) | -€17.57m |
| Revenue (TTM) | €14.95m |
2.1x
P/S Ratio-1.8x
P/E RatioIs 43 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 43 income statement (TTM) | |
|---|---|
| Revenue | US$16.03m |
| Cost of Revenue | US$2.80m |
| Gross Profit | US$13.23m |
| Other Expenses | US$32.06m |
| Earnings | -US$18.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.14 |
| Gross Margin | 82.51% |
| Net Profit Margin | -117.49% |
| Debt/Equity Ratio | 0% |
How did 43 perform over the long term?
See historical performance and comparison